NYSE
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.4M | $22,000.00 | $14,000.00 | $442,000.00 | $420,000.00 | $819,000.00 |
| Gross profit | -$1.9M | -$1.5M | -$147,000.00 | $412,000.00 | $378,000.00 | $756,000.00 |
| Operating income | -$35.4M | -$29.3M | -$27.0M | -$78.1M | -$11.2M | -$21.1M |
| Net income | -$36.0M | -$25.1M | -$26.9M | -$70.6M | -$16.6M | -$17.2M |
| Diluted EPS | — | -$248.22 | -$25.98 | — | — | — |
| Operating cash flow | -$28.3M | -$27.6M | -$22.6M | -$20.6M | -$9.3M | -$8.3M |
| Free cash flow | -$28.4M | -$27.9M | -$22.6M | -$20.7M | -$9.3M | -$8.3M |
| Gross margin | -43.4% | -6990.9% | -1050.0% | 93.2% | 90.0% | 92.3% |
| Operating margin | -803.7% | -133027.3% | -192578.6% | -17674.0% | -2676.9% | -2581.6% |
| Net margin | -818.3% | -113954.5% | -191892.9% | -15966.5% | -3962.6% | -2098.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93,000.00 | $96,000.00 | $149,000.00 | $143,000.00 | $212,000.00 | $226,000.00 | $238,000.00 | $432,000.00 |
| Gross profit | $77,000.00 | $86,000.00 | $138,000.00 | $132,000.00 | $198,000.00 | $208,000.00 | $218,000.00 | $390,000.00 |
| Operating income | -$2.7M | -$2.9M | -$3.1M | -$3.6M | -$4.7M | -$3.0M | -$9.9M | -$2.3M |
| Net income | -$4.2M | -$4.1M | -$5.6M | -$4.0M | -$5.1M | -$2.3M | -$5.8M | -$1.7M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$1.7M | -$2.8M | -$2.9M | -$2.3M | -$2.3M | -$2.2M | -$1.5M | -$2.8M |
| Free cash flow | -$1.7M | -$2.8M | -$2.9M | -$2.3M | -$2.3M | -$2.2M | -$1.5M | -$2.8M |
| Gross margin | 82.8% | 89.6% | 92.6% | 92.3% | 93.4% | 92.0% | 91.6% | 90.3% |
| Operating margin | -2921.5% | -2978.1% | -2047.7% | -2500.0% | -2210.4% | -1336.7% | -4143.3% | -536.6% |
| Net margin | -4537.6% | -4291.7% | -3777.2% | -2828.7% | -2409.9% | -996.0% | -2427.7% | -389.1% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.